+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries

  • ID: 2858972
  • Report
  • Region: Global
  • 91 Pages
  • GBI Research
1 of 5
Market to Decline due to Key Patent Expiries

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Merck
  • Novartis
  • Pfizer
  • Speedel
  • MORE
'‘Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'', provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter.

The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the hypertension in the major developed markets.The report includes:

- Disease overview, as well as treatment algorithms and treatment use patterns
- Market size and forecast for the hypertension market from 2013-2020
- Major marketed products for hypertension along with a heat map of product performance
- In-depth pipeline analysis for global pipeline in hypertension along with clinical trial failure rate analysis
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

The report will enhance your decision-making capability by allowing you to:

- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the hypertension therapeutics market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Merck
  • Novartis
  • Pfizer
  • Speedel
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Pathophysiology
2.2 Etiology
2.3 Signs and Symptoms
2.4 Co-Morbidities and Complications
2.5 Diagnosis
2.5.1 Office Blood Pressure Monitoring
2.5.2 Ambulatory Blood Pressure Monitoring
2.5.3 Home Blood Pressure Monitoring
2.5.4 Miscellaneous Methods
2.5.5 Diagnosis of Target Organ Damage
2.5.6 Diagnosis of Hypertension in Pregnancy
2.6 Classification
2.7 Epidemiology
2.8 Prognosis
2.9 Treatment and Management
2.9.1 Treatment Strategy

3 Marketed Products
3.1 Approved Products
3.1.1 Norvasc (amlodipine besylate) - Pfizer
3.1.2 Micardis (telmisartan) - Boehringer Ingelheim
3.1.3 Tekturna (aliskiren) - Novartis/Speedel
3.1.4 Benicar (olmesartan medoxomil) - Daiichi Sankyo
3.1.5 Diovan (valsartan) - Novartis
3.1.6 Cozaar (losartan) - Merck
3.1.7 Exforge (amlodipine + valsartan) - Novartis
3.2 Comparative Efficacy and Safety

4 Product Pipeline
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecules Type
4.3 Pipeline Analysis by Mechanism of Action Type
4.4 Clinical Trial Failure Rate
4.5 Patient Enrollment and Clinical Trial Size
4.6 Clinical Trial Duration
4.7 Promising Drug Candidates in Pipeline
4.7.1 LCZ696 (AHU-377 + valsartan) - Novartis

5 Market Forecast
5.1 Introduction
5.2 Global Market
5.3 North America
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Revenue
5.4 Top Five European Countries
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Revenue
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Revenue
5.6 Drivers and Barriers
5.6.1 Drivers
5.6.2 Barriers

6 Deals and Strategic Consolidations
6.1 Licensing Deals
6.1.1 Bristol-Myers Squibb Enters into Licensing Agreement with Kyowa Hakko Kirin for Coniel in China
6.1.2 Takeda Pharma Enters into Licensing Agreement with Arbor Pharma for Edarbi and Edarbyclor
6.1.3 Lorus Therapeutics Enters into Licensing Agreement with Zor Pharma
6.1.4 Nippon Shinyaku Signs Licensing Agreement with Eli Lilly
6.2 Co-development Deals
6.2.1 AnGes Enters into Co-development Agreement with BioLeaders for Hypertension Vaccine
6.2.2 Takeda Enters into Co-development Agreement with Covance
6.2.3 Boehringer Ingelheim Enters into an Agreement with Vitae Pharma
6.2.4 NicOx Expands Research Collaboration with Merck

7 Appendix
7.1 Market Forecasts to 2020
7.2 All Pipeline Drugs by Phase
7.2.1 Discovery
7.2.2 Preclinical
7.2.3 Phase I
7.2.4 Phase II
7.2.5 Phase III
7.3 Abbreviations
7.4 References
7.5 Methodology
7.5.1 Coverage
7.5.2 Secondary Research
7.5.3 Primary Research
7.5.4 Therapeutic Landscape
7.5.5 Geographical Landscape
7.5.6 Pipeline Analysis
7.6 Expert Panel Validation
7.7 Contact Us
7.8 Disclaimer

1.1 List of Tables

Table 1: Anti-Hypertensives Market, Possible Co-Morbidities
Table 2: Anti-Hypertensives Market, Blood Pressure Classification in Adults
Table 3: Anti-Hypertensives Market, Prevalence Rate (%)
Table 4: Anti-Hypertensives Market, Initiation of Treatment
Table 5: Anti-Hypertensives Market, Lifestyle Management
Table 6: Anti-Hypertensives Market, Major Developed Market, Forecast Data, 2013-2020
Table 7: Anti-Hypertensives Market, US, Forecast Data, 2013-2020
Table 8: Anti-Hypertensives Market, UK, Forecast Data, 2013-2020
Table 9: Anti-Hypertensives Market, France, Forecast Data, 2013-2020
Table 10: Anti-Hypertensives Market, Germany, Forecast Data, 2013-2020
Table 11: Anti-Hypertensives Market, Italy, Forecast Data, 2013-2020
Table 12: Anti-Hypertensives Market, Spain, Forecast Data, 2013-2020
Table 13: Anti-Hypertensives Market, Japan, Forecast Data, 2013-2020
Table 14: Anti-Hypertensives Market, Canada, Forecast Data, 2013-2020
Table 15: Anti-Hypertensives Market, Global, Developmental Pipeline, Discovery Phase
Table 16: Anti-Hypertensives Market, Global, Developmental Pipeline, Preclinical Phase
Table 17: Anti-Hypertensives Market, Global, Developmental Pipeline, Phase I
Table 18: Anti-Hypertensives Market, Developmental Pipeline, Phase II
Table 19: Anti-Hypertensives Market, Developmental Pipeline Phase III, 2013
Table 20: Anti-Hypertensives Market, Therapeutics, Abbreviations

1.2 List of Figures

Figure 1: Anti-Hypertensives Market, Global, Prevalence Rate (%), 2007-2010
Figure 2: Anti-Hypertensives Market, Treatment Algorithm, 2013
Figure 3: Anti-Hypertensives Market, Global, Norvasc (amlodipine besylate) Revenue ($bn), 2005-2013
Figure 4: Anti-Hypertensives Market, Global, Micardis (telmisartan), Revenue ($bn), 2005-2013
Figure 5: Anti-Hypertensives Market, Global, Tekturna (aliskiren) Revenue ($m), 2007-2013
Figure 6: Anti-Hypertensives Market, Global, Benicar (olmesartan), Revenue ($bn), 2005-2013
Figure 7: Anti-Hypertensives Market, Global, Diovan (valsartan) Revenue ($bn), 2005-2013
Figure 8: Anti-Hypertensives Market, Global, Cozaar (losartan), Revenue ($bn), 2005-2013
Figure 9: Anti-Hypertensives Market, Global, Exforge (amlodipine + valsartan), Revenue ($bn), 2007-2013
Figure 10: Anti-Hypertensives Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013
Figure 11: Anti-Hypertensives Market, Global, Pipeline Distribution by Stage, Program Type and Route of Administration, 2013
Figure 12: Anti-Hypertensives Market, Global, Pipeline by Molecule Type and Stage of Development, 2013
Figure 13: Anti-Hypertensives Market, Global, Pipeline by Mechanism of Action, 2013
Figure 14: Anti-Hypertensives Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development, 2013
Figure 15: Anti-Hypertensives Market, Global, Clinical Trial Failure Rate (%), 2013
Figure 16: Anti-Hypertensives Market, Global, Clinical Trial Failure Rate (%), 2006-2013
Figure 17: Anti-Hypertensives Market, Global, Clinical Trial Size (Participants), 2013
Figure 18: Anti-Hypertensives Market, Global, Pipeline Clinical Trial Duration (Months), 2013
Figure 19: Anti-Hypertensives Market, Global, Treatment Usage Patterns and Market Revenue ($bn), 2013-2020
Figure 20: Anti-Hypertensives Market, US and Canada, Treatment Usage Patterns, 2013-2020
Figure 21: Anti-Hypertensives Market, US and Canada, Annual Cost of Therapy ($), 2013-2020
Figure 22: Anti-Hypertensives Market, US and Canada, Market Revenue ($bn), 2013-2020
Figure 23: Anti-Hypertensives Market, Top Five European Markets, Treatment Usage Patterns, 2013-2020
Figure 24: Anti-Hypertensives Market, Top Five European Markets, Annual Cost of Therapy ($), 2013-2020
Figure 25: Anti-Hypertensives Market, Top Five European Markets, Market Revenue ($bn), 2013-2020
Figure 26: Anti-Hypertensives Market, Japan, Treatment Usage Patterns, 2013-2020
Figure 27: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2013-2020
Figure 28: Anti-Hypertensives Market, Japan, Market Revenue ($bn), 2013-2020
Figure 29: Anti-Hypertensives Market, Global Deals by Value, Year and Stage of Development, 2006-2013
Figure 30: Anti-Hypertensives Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006-2013
Figure 31: Anti-Hypertensives Market, Global, Licensing Deals by Geography, 2006-2013
Figure 32: Anti-Hypertensives Market, Global, Co-Development Deals by Region, Value ($m) and Year, 2006-2013
Figure 33: Market Forecasting Model
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Merck
  • Novartis
  • Pfizer
  • Speedel
  • MORE
Market to Decline due to Key Patent Expiries

The global anti-hypertensives market is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% from $40 billion in 2013 to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan).

However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017. Hypertension is a chronic disease and so its management required prolonged treatment. The management of hypertension requires prolonged treatment as it is a chronic disease, ultimately ensuring market stability despite generic erosion.

Anti-Hypertensives Pipeline: Limited Scope

Most of the drugs in the anti-hypertensives pipeline are generics (77%), and only 20% of molecules are novel drug candidates. The novel approach is limited to a few targets such as nondihydropyridine dual L/T-type calcium channel blockers (ACT-280778), Rho-associated kinase inhibitors (AN-3485), and vitamin D receptor agonists (CARD-024), to name a few. Novartis' AHU-377, a novel molecule that functions as a Neutral Endopeptidase Inhibitor (NEP), is currently in Phase III as a combination drug with Novartis' blockbuster valsartan. Most of the drug dosages in the anti-hypertension market comprise one oral tablet once daily.
Note: Product cover images may vary from those shown
5 of 5
- Boehringer Ingelheim
- Daiichi Sankyo
- Merck
- Novartis
- Pfizer
- Speedel
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/2858972
Adroll
adroll